title: The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
abstract: We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [-81.1 mU/ml mean difference; 95% confidence intervals (95% CI): -30.3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen.
authors.affiliation: Institute of Infectious and Tropical Diseases, Spedali Civili, University of Brescia, Brescia, Italy. m.puoti@iol.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Puoti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Cozzi-Lepri
authors.forename: Fausto
authors.initials: F
authors.lastname: Ancarani
authors.forename: Raffaele
authors.initials: R
authors.lastname: Bruno
authors.forename: Silvia
authors.initials: S
authors.lastname: Ambu
authors.forename: Teresa
authors.initials: T
authors.lastname: Ferraro
authors.forename: Paolo
authors.initials: P
authors.lastname: Tundo
authors.forename: Teresa
authors.initials: T
authors.lastname: Santantonio
authors.forename: Mario
authors.initials: M
authors.lastname: Toti
authors.forename: Marino
authors.initials: M
authors.lastname: Bonasso
authors.forename: Antonella
authors.initials: A
authors.lastname: d'Arminio Monforte
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000378:metabolism; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001219:Aspartate Aminotransferases / Q000378:metabolism; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D008099:Liver / Q000201:enzymology; D008297:Male; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase